Ulrik Ringborg

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: EUROPEAN JOURNAL OF CANCER. 2014;50(16):2745-2746
Cancer Core Europe: A consortium to address the cancer care - Cancer research continuum challenge
Eggermont AMM; Caldas C; Ringborg U; Medema R; Tabernero J; Wiestler O
Article: JOURNAL OF ONCOLOGY PRACTICE. 2014;10(5):e342-e349
Pioneering Quality Assessment in European Cancer Centers: A Data Analysis of the Organization for European Cancer Institutes Accreditation and Designation Program
Saghatchian M; Thonon F; Boomsma F; Hummel H; Koot B; Harrison C; Rajan A; de Valeriola D; Otter R; Pontes JL; Lombardo C; McGrath E; Ringborg U; Tursz T; van Harten W
Article: ECANCERMEDICALSCIENCE. 2012;6:ed13
EurocanPlatform, an FP7 project of the European Commission-first year commentary.
McVie G; Ringborg U
Article: LANCET. 2011;378(9803):1635-1642
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial
Gillgren P; Drzewiecki KT; Niin M; Gullestad HP; Hellborg H; Mansson-Brahme E; Ingvar C; Ringborg U
Article: CANCER RESEARCH. 2009;69(9):3746-3754
Species-Specific In vivo Engraftment of the Human BL Melanoma Cell Line Results in an Invasive Dedifferentiated Phenotype Not Present in Xenografts
Cedervall J; Jamil S; Prasmickaite L; Cheng Y; Eskandarpour M; Hansson J; Maelandsmo GM; Ringborg U; Gulyas M; Zhen HS; Kanter L; Ahrlund-Richter L
Article: LAKARTIDNINGEN. 2008;105(39):2666-2669
[Nevus or malignant melanoma? Correct diagnostic competence results in lower costs].
Lindelöf B; Hedblad M-A; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 2008;44(6):772-773
Managing cancer in the EU: The Organisation of European Cancer Institutes (OECI)
Ringborg U; Pierotti M; Storme G; Tursz T
Article: MELANOMA RESEARCH. 2006;16(2):197-200
Mutations of PIK3CA are rare in cutaneous melanoma
Omholt K; Kröckel D; Ringborg U; Hansson J
Article: EUROPEAN JOURNAL OF CANCER. 2005;41(14):2141-2149
A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe
Bataille W; Boniol M; De Vries E; Severi G; Brandberg Y; Sasieni P; Cuzick J; Eggermont A; Ringborg U; Grivegnée AR; Coebergh JW; Chignol MC; Doré JF; Autier P
Article: CLINICAL CANCER RESEARCH. 2005;11(8):2991-2997
Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival
Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
Article: MELANOMA RESEARCH. 2005;15(2):125-132
Effect of primary site on prognosis in patients with cutaneous malignant melanoma.: A study using a new model to analyse anatomical locations
Gillgren P; Brattström G; Frisell J; Persson JO; Ringborg U; Hansson J
Article: MELANOMA RESEARCH. 2004;14(5):395-401
P53 protein expression and TP53 mutations in malignant melanomas of sun-sheltered mucosal membranes versus chronically sun-exposed skin
Ragnarsson-Olding B; Platz A; Olding L; Ringborg U
Article: CLINICAL CANCER RESEARCH. 2003;9(17):6483-6488
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Article: BRITISH JOURNAL OF CANCER. 2003;89(8):1517-1523
O⁶-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma
Ma S; Egyházi S; Ueno T; Lindholm C; Kreklau EL; Stierner U; Ringborg U; Hansson J
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2003;44(8):3282-3287
Uveal melanoma survival in Sweden from 1960 to 1998
Bergman L; Seregard S; Nilsson B; Lundell G; Ringborg U; Ragnarsson-Olding B
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2003;95(11):790-798
Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations
Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
Article: MELANOMA RESEARCH. 2003;13(3):279-286
Body site of cutaneous malignant melanoma -: a study on patients with hereditary and multiple sporadic tumours
Gillgren P; Brattström G; Frisell J; Palmgren J; Ringborg U; Hansson J
Article: ACTA ONCOLOGICA. 2003;42(5-6):366-375
Radiotherapy and cancer care in Sweden
Möller TR; Einhorn N; Lindholm C; Ringborg U; Svensson H
Article: ACTA ONCOLOGICA. 2003;42(5-6):357-365
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001 -: Summary and conclusions
Ringborg U; Bergqvist D; Brorsson B; Cavallin-Ståhl E; Ceberg J; Einhorn N; Frödin JE; Järhult J; Lamnevik G; Lindholm C; Littbrand B; Norlund A; Nylén U; Rosén W; Svensson H; Möller TR
Article: CLINICAL CANCER RESEARCH. 2002;8(11):3468-3474
Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas:: Mutations occur early and persist throughout tumor progression
Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
Article: HUMAN MUTATION. 2002;20(5):408-409
Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden.
Egyházi S; Ma S; Smoczynski K; Hansson J; Platz A; Ringborg U
Article: ONCOLOGY REPORTS. 2002;9(5):1015-1019
Immunohistochemical analysis of DNA mismatch repair protein and O⁶-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy
Ma S; Egyházi S; Ringborg U; Hansson J
Article: MELANOMA RESEARCH. 2002;12(4):335-342
Analysis of O⁶-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy
Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2002;43(8):2579-2583
Incidence of uveal melanoma in Sweden from 1960 to 1998
Bergman L; Seregard S; Nilsson B; Ringborg U; Lundell G; Ragnarsson-Olding B
Article: BRITISH JOURNAL OF DERMATOLOGY. 2002;146(6):1023-1030
A new computerized methodology to analyse tumour site in relation to phenotypic traits and epidemiological characteristics of cutaneous malignant melanoma
Gillgren P; Brattström G; Mårtensson ED; Frisell J; Palmgren J; Ringborg U; Hansson J
Article: ACTA ONCOLOGICA. 2002;41(2):138-146
Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994
Mansson-Brahme E; Johansson H; Larsson O; Rutqvist LE; Ringborg U
Article: NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM INTERACTIONS WITH MATERIALS AND ATOMS. 2001;184(4):569-588
Design of a centre for biologically optimised light ion therapy in Stockholm
Brahme A; Lewensohn R; Ringborg U; Amaldi U; Gerardi F; Rossi S
Article: ACTA DERMATO-VENEREOLOGICA. 2001;81(4):268-272
Increasing incidence rates of squamous cell carcinoma of the skin in Sweden
Wassberg C; Thörn M; Johansson AM; Bergström R; Berne B; Ringborg U
Article: INTERNATIONAL JOURNAL OF CANCER. 2001;92(6):839-842
Cytoplasmic and nuclear accumulation of β-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma
Omholt K; Platz A; Ringborg U; Hansson J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2001;19(3):824-831
Serum S-100B protein as a prognostic marker in malignant cutaneous melanoma
Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Brahme EM; Ringborg U; Hansson J
Article: CANCER RESEARCH. 2000;60(24):6864-6867
CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Article: CANCER. 2000;89(7):1495-1501
Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm
Cohn-Cedermark G; Rutqvist LE; Andersson R; Breivald M; Ingvar C; Johansson H; Jönsson PE; Krysander L; Lindholm C; Ringborg U
Article: LARYNGOSCOPE. 2000;110(9):1498-1504
A prospective population-based study of cutaneous malignant melanoma of the head and neck
Gillgren P; Månsson-Brahme E; Frisell J; Johansson H; Larsson O; Ringborg U
Article: MELANOMA RESEARCH. 2000;10(4):363-369
The value of cysteinyldopa in the follow-up of disseminated malignant melanoma
Kärnell R; Kågedal B; Lindholm C; Nilsson B; Årstrand K; Ringborg U
Article: SEMINARS IN CANCER BIOLOGY. 2000;10(4):319-326
Hereditary cutaneous melanoma
Platz A; Ringborg U; Hansson J
Article: CANCER. 2000;89(2):348-355
Trends in mortality from malignant melanoma in Sweden, 1970-1996
Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Johansson H; Ringborg U
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;83(3):314-317
Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ
Wassberg C; Thörn M; Yuen J; Hakulinen T; Ringborg U
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;80(4):511-515
Second primary cancers in patients with squamous cell carcinoma of the skin:: A population-based study in Sweden
Wassberg C; Thörn M; Yuen J; Ringborg U; Hakulinen T
Article: ACTA ONCOLOGICA. 1999;38(8):1069-1074
Epidemiological characteristics of cutaneous malignant melanoma of the head and neck -: A population-based study
Gillgren P; Månsson-Brahme E; Frisell J; Johansson H; Larsson O; Ringborg U
Article: ACTA ONCOLOGICA. 1999;38(5):549-557
Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma
Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Singnomklao T; Ringborg U
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 1998;111(5):757-761
N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membrane or unexposed skin
Jiveskog S; Ragnarsson-Olding B; Platz A; Ringborg U
Article: MELANOMA RESEARCH. 1998;8(5):403-411
Nodular histogenetic type - the most significant factor for thick melanoma: implications for prevention
Bergenmar M; Ringborg U; Brahme EM; Brandberg Y
Article: ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH. 1998;22(7 Suppl):323S-328S
Alcohol and risk of cancer.
Ringborg U
Article: INTERNATIONAL JOURNAL OF CANCER. 1998;78(1):13-15
Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma:: A clinic-based population study
Platz A; Hansson J; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1998;34(9):1368-1374
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma.: A randomised phase III trial
Jungnelius U; Ringborg U; Aamdal S; Mattsson J; Stierner U; Ingvar C; Malmström P; Andersson R; Karlsson M; Willman K; Wist E; Bjelkengren G; Westberg R
Article: ACTA ONCOLOGICA. 1998;37(5):463-470
Central nervous system metastases of cutaneous malignant melanoma -: A population-based study
Cohn-Cedermark G; Månsson-Brahme E; Rutqvist LE; Larsson O; Johansson H; Ringborg U
Article: ANTICANCER RESEARCH. 1997;17(4B):3071-3073
Prognostic value of serum analyses of S-100 protein beta in malignant melanoma
Hansson LO; VonSchoultz E; Djureen E; Hansson J; Nilsson B; Ringborg U
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1997;89(10):697-702
Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma
Platz A; Hansson J; ManssonBrahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganas M; Ringborg U
Article: RADIOTHERAPY AND ONCOLOGY. 1997;43(1):23-28
Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: A randomized Phase III study
Lewin F; Damber L; Jonsson H; Andersson T; Berthelsen A; Biorklund A; Blomqvist E; Evensen JF; Hansen HS; Hansen O; Jetlund O; Mercke C; Modig H; Overgaard M; Rosengren B; Tausjo J; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(3):447-452
Role of O-6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line
Egyhazi S; Edgren MR; Hansson J; Krockel D; Mannervik B; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(1):129-134
Immunohistochemical examination of the expression of O-6-methylguanine-DNA methyltransferase in human melanoma metastases
Egyhazi S; Margison GP; Hansson J; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1996;32A(11):1893-1900
Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung
Brodin O; Nou E; Mercke C; Linden CJ; Lundstrom R; Arwidi A; Brink J; Ringborg U
Article: BRITISH JOURNAL OF CANCER. 1996;74(6):936-941
Genes involved in cell cycle G(1) checkpoint control are frequently mutated in human melanoma metastases
Platz A; Sevigny P; Norberg T; Ring P; Lagerlof B; Ringborg U
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;67(1):38-44
Predictors of late mortality in cutaneous malignant melanoma - A population-based study in Sweden
Thorn M; Bergstrom R; Hedblad M; Lagerlof B; Ringborg U; Adami HO
Article: ANTI-CANCER DRUGS. 1996;7(4):422-429
Inhibition of tumor cell growth by monoterpenes in vitro: Evidence of a Ras-independent mechanism of action
Karlson J; BorgKarlson AK; Unelius R; Shoshan MC; Wilking N; Ringborg U; Linder S
Article: CANCER. 1996;77(9):1809-1814
Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm - A randomized study by the Swedish melanoma study group
Ringborg U; Andersson R; Eldh J; Glaumann B; Hafstrom L; Jacobsson S; Jonsson PE; Johansson H; Krysander L; Lagerlof B; Christer L; Bjorn N; CarlMagnus R; Erik RL; Gunnar W; Athlin L; Bergman O; Carlsson L; Cosmo P; Danielsson H; Eriksson M; Grenabo J; Gustavsson L; Haghjoo A; Holmner S; Hogman L; Ingvar C; Jansson K; Jaska F; Lindmark L; Moell PO; Mossberg I; Ohlsson E; Persson NA; Segerstrom A; Sellstrom H; Tholin B; Widman BG; Wiren M; Ohrn PG
Article: MELANOMA RESEARCH. 1996;6(2):133-137
Prognostic value of serum analyses of S-100 beta protein in malignant melanoma
vonSchoultz E; Hansson LO; Djureen E; Hansson J; Karnell A; Nilsson B; Stigbrand T; Ringborg U
Article: PREVENTIVE MEDICINE. 1996;25(2):170-177
Perceived susceptibility to and knowledge of malignant melanoma: Screening participants vs the general population
Brandberg Y; Bolund C; Michelson H; ManssonBrahme E; Ringborg U; Sjoden PO
Article: BRITISH JOURNAL OF CANCER. 1996;73(3):344-348
Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma
Platz A; Ringborg U; Lagerlof B; Lundqvist E; Sevigny P; Inganas M
Article: ACTA ONCOLOGICA. 1996;35(6):683-690
Increased cisplatin sensitivity of human fibroblasts from a subject with inherent glutathione deficiency
Hansson J; Edgren MR; Egyhazi S; Hao XY; Mannervik B; Ringborg U
Article: JOURNAL OF MEDICAL SCREENING. 1996;3(4):211-215
Screening for cutaneous malignant melanoma: a feasibility study.
Törnberg S; Månsson-Brahme E; Lindén D; Ringborg U; Krakau I; Kärnell R; Landegren J; Brandberg Y; Hakulinen T
Article: BRITISH JOURNAL OF CANCER. 1996;73(2):255-259
Second primary cancers in patients with cutaneous malignant melanoma: A population-based study in Sweden
Wassberg C; Thorn M; Yuen J; Ringborg U; Hakulinen T
Article: OPHTHALMOLOGY. 1995;102(10):1524-1529
PREVALENCE OF PRIMARY ACQUIRED MELANOSIS AND NEVI OF THE CONJUNCTIVA AND UVEA IN THE DYSPLASTIC NEVUS SYNDROME - A CASE-CONTROL STUDY
SEREGARD S; AFTRAMPE E; MANSSONBRAHME E; KOCK E; BERGENMAR M; RINGBORG U
Article: ANTI-CANCER DRUGS. 1995;6(3):465-470
THE EFFECT OF 5-FLUOROURACIL ON CISPLATIN-INDUCED DNA INTERSTRAND CROSS-LINKING IN A MOUSE ASCITES TUMOR GROWING IN-VIVO
LEWIN F; RINGBORG U; SKOG S; TRIBUKAIT B
Article: MELANOMA RESEARCH. 1995;5(2):113-116
Tyrosinase activity in the serum of patients with malignant melanoma.
Sonesson B; Eide S; Ringborg U; Rorsman H; Rosengren E
Article: MELANOMA RESEARCH. 1995;5(2):101-106
IMMUNOHISTOCHEMICAL ANALYSIS OF THE N-RAS P21 AND THE P53 PROTEINS IN NEVI, PRIMARY TUMORS AND METASTASES OF HUMAN CUTANEOUS MALIGNANT-MELANOMA - INCREASED IMMUNOPOSITIVITY IN HEREDITARY MELANOMA
PLATZ A; RINGBORG U; GRAFSTROM E; HOOG A; LAGERLOF B
Article: ACTA ONCOLOGICA. 1995;34(1):35-41
THE EXPRESSION OF GLUTATHIONE TRANSFERASE ISOENZYMES IN HUMAN-MALIGNANT LYMPHOMA BIOPSIES
BERHANE K; HAO XY; CHRISTENSSON B; HANSSON J; RINGBORG U; MANNERVIK B
Article: EUROPEAN JOURNAL OF CANCER. 1995;31A(2):157-162
PSYCHOLOGICAL REACTIONS IN PATIENTS WITH MALIGNANT-MELANOMA
BRANDBERG Y; MANSSONBRAHME E; RINGBORG U; SJODEN PO
Article: ACTA ONCOLOGICA. 1995;34(6):759-765
GLUTATHIONE TRANSFERASE P1-1 EXPRESSION IN HUMAN-MELANOMA METASTASES - CORRELATION TO N-RAS MUTATIONS AND EXPRESSION
PLATZ A; JUNGNELIUS U; GRAFSTROM E; LAGERLOF B; MANNERVIK B; RINGBORG U
Visa fler

Alla övriga publikationer

Editorial comment: SCIENCE TRANSLATIONAL MEDICINE. 2015;7(297):297fs31
Optimizing sharing of hospital biobank samples
Riegman PHJ; de Jong B; Daidone MG; Soderstrom T; Thompson J; Hall JA; Mendy M; ten Hoeve J; Broeks A; Reed W; Morente MM; Antonio Lopez-Guerrero J; Collins VP; Rogan J; Ringborg U
Editorial comment: MOLECULAR ONCOLOGY. 2015;9(5):933-934
Innovative clinical trials for development of personalized cancer medicine
Mendelsohn J; Ringborg U; Schilsky R
Editorial comment: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2015;107(1):353-5
Translational Cancer Research: Balancing Prevention and Treatment to Combat Cancer Globally
Wild CP; Bucher JR; de Jong BWD; Dillner J; von Gertten C; Groopman JD; Herceg Z; Holmes E; Holmila R; Olsen JH; Ringborg U; Scalbert A; Shibata T; Smith MT; Ulrich C; Vineis P; McLaughlin J
Editorial comment: MOLECULAR ONCOLOGY. 2014;8(7):1161-1162
Cancer Core Europe: A first step towards a virtual cancer institute in Europe?
Celis JE; Ringborg U
Review: AMERICAN SOCIETY OF CLINICAL ONCOLOGY EDUCATIONAL BOOK / ASCO. AMERICAN SOCIETY OF CLINICAL ONCOLOGY. MEETING. 2013;:118-125
Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
Tsimberidou AM; Ringborg U; Schilsky RL
Editorial comment: MOLECULAR ONCOLOGY. 2012;6(2):109-110
Personalized cancer medicine - A strategy to counteract an increasing cancer challenge
Mendelsohn J; Ringborg U; Schilsky RL
Other: LAKARTIDNINGEN. 2009;106(15-16):1112
[Correct about skin cancer costs].
Lindelöf B; Hedblad M-A; Ringborg U
Editorial comment: ANNALS OF ONCOLOGY. 2008;19(9):1519-1521
Need for global action for cancer control
Boyle P; Anderson BO; Andersson LC; Ariyaratne Y; Auleley G-R; Barbacid M; Bartelink H; Baselga J; Behbehani K; Belardelli F; Berns A; Bishop J; Brawley O; Burns H; Clanton M; Cox B; Currow D; Dangou J-M; de Valeriola D; Dinshaw K; Eggermont A; Fitzpatrick J; Forstmane M; Garaci E; Gavin AT; Kakizoe T; Kasler M; Keita N; Kerr D; Khayat D; Khleif S; Khuhaprema T; Knezevic T; Kubinova R; Mallath M; Martin-Moreno J; McCance D; McVie JG; Merriman A; Ngoma T; Nowacki M; Orgelbrand J; Park J-G; Pierotti M; Ashton LP; Puska P; Escobar CVR; Rajan B; Rajkumar T; Ringborg U; Robertson C; Rodger A; Roovali L; Santini LA; Sarhan M; Seffrin J; Semiglazov V; Shrestha BM; Soo KC; Stamenic V; Tamblyn C; Thomas R; Tuncer M; Tursz T; Vaitkiene R; Vallejos C; Veronesi U; Wojtyla A; Yach D; Yoo K-Y; Zatonski W; Zaridze D; Zeng Y-X; Zhao P; Zheng T
Letter: MOLECULAR ONCOLOGY. 2008;2(1):10-11
The Stockholm Declaration
Ringborg U
Published conference paper: TUMORI JOURNAL. 2008;94(2):164-171
Towards quality, comprehensiveness and excellence. The accreditation project of the Organisation of European Cancer Institutes (OECI)
Saghatchian M; Hummel H; Otter R; de Valeriola D; Van Harten W; Paradiso A; Koot B; Ringborg U; Tursz T
Published conference paper: TUMORI JOURNAL. 2008;94(2):143-146
Improvement of European translational cancer research. Collaboration between comprehensive cancer centers
Ringborg U; de Valeriola D; van Harten W; Llombart Bosch A; Lombardo C; Nilsson K; Philip T; Pierotti MA; Riegman P; Saghatchian M; Storme G; Tursz T; Verellen D
Editorial comment: ACTA ONCOLOGICA. 2008;47(2):171-175
Swedish oncology. Past-present-future
Ringborg U
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2007;25(19):2819-2824
Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome:: Results of a Swedish preventive program
Hansson J; Bergenmar M; Hofer P-A; Lundell G; Mansson-Brahme E; Ringborg U; Synnerstad I; Bratel AT; Wennberg A-M; Rosdahl I
Other: MELANOMA RESEARCH. 2007;17(1):56-58
Interferon therapy discussed at the Sixth International Conference on the Adjuvant Therapy of Malignant Melanoma, Stockholm, Sweden, 15-17 June 2006.
Ringborg U; Pownall M
Editorial comment: LANCET. 2006;367(9524):1710-1712
Tobacco: deadly in any form or disguise
Boyle P; Ariyaratne MAY; Barrington R; Bartelink H; Bartsch G; Berns A; de Valeriola D; Dinshaw KA; Eggermont AMM; Gray N; Kakizoe T; Karki BS; Kaslar M; Kerr DJ; Khayat D; Khuhaprema T; Kim I-H; Martin-Moreno J; McVie G; Park J-G; Philip T; Ringborg U; Rodger A; Seffrin JR; Semiglazov V; Soo KC; Sun Y-T; Thomas R; Tursz T; Veronesi U; Wiestler O; Yoo K-Y; Zatonski W; Zhao P
Review: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 2006;587:87-93
Harmonizing cancer control in Europe.
Ringborg U
Editorial comment: LANCET. 2005;365(9476):1990-1992
Curbing tobacco's toll starts with the professionals:: World No Tobacco Day
Boyle P; Ariyaratne MAY; Bartelink H; Baselga J; Berns A; Brawley OW; Burns H; Davidov MH; Dinshaw KA; Dresler C; Eggermont AMM; Gajurel D; Gordina G; Gray N; Kakizoe T; Karki BS; Kásler M; Kerr DJ; Khayat D; Kiselev A; Khuhaprema T; Klocker H; Levshin V; Martin-Moreno JM; McVie JG; Mendelsohn J; Napalkov NP; Ngoma TA; Park JG; Philip T; Pötschke-Langer M; Poudal HN; Rajan B; Ringborg U; Rodger A; Seffrin JR; Shanta V; Shrestha MM; Thomas R; Tursz T; de Valeriola D; Veronesi U; Wiestler OD; Zaridze D; Zatonski W; Zeng YX
Published conference paper: RADIOTHERAPY AND ONCOLOGY. 2004;73:S206-S210
Development of light ion therapy at the Karolinska Hospital and Institute
Svensson H; Ringborg U; Näslund I; Brahme A
Letter: CLINICAL CHEMISTRY. 2004;50(5):975-976
Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies
Egyházi S; Bjöhle J; Skoog L; Huang F; Borg AL; Stolt MF; Hägerström T; Ringborg U; Bergh J
Editorial comment: ANNALS OF ONCOLOGY. 2004;15(1):5-6
Cancer of the skin:: a forgotten problem in Europe
Boyle P; Doré JF; Autier P; Ringborg U
Review: ANNALS OF ONCOLOGY. 2003;14(7):973-1005
European Code Against Cancer and scientific justification: third version (2003)
Boyle P; Autier P; Bartelink H; Baselga J; Boffetta P; Burn J; Burns HJG; Christensen L; Denis L; Dicato M; Diehl V; Doll R; Franceschi S; Gillis CR; Gray N; Griciute L; Hackshaw A; Kasler M; Kogevinas M; Kvinnsland S; La Vecchia C; Levi F; McVie JG; Maisonneuve P; Martin-Moreno JM; Bishop JN; Oleari F; Perrin P; Quinn M; Richards M; Ringborg U; Scully C; Siracka E; Storm H; Tubiana M; Tursz T; Veronesi U; Wald N; Weber W; Zaridze DG; Zatonski W; zur Hausen H
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1999;35:S370-S371
Vulvar melanoma are different from cutaneous melanoma
Ragnarsson-Olding B; Kanter-Lewensohn L; Lagerlöf B; Nilsson B; Ringborg U
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1999;35:S369
CDKN2A germline mutations in Swedish kindreds with hereditary cutaneous melanomas
Hansson J; Platz A; Hashemi J; Stierner U; Ringborg U
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 1999;35:S369
Genetic analysis of N-ras and CDKN2A in sporadic primary melanomas and their metastases
Platz A; Karsberg S; Ringborg U
Letter: MELANOMA RESEARCH. 1999;9(3):304
Nodular histogenetic type - the most significant factor for thick melanoma: implications for prevention. Response
Bergenmar M; Ringborg U; Brahme EM; Brandberg Y; Larsson O
Published conference paper: CANCER. 1997;80(8):1418-1425
Outcomes of patients with local recurrence of cutaneous malignant melanoma - A population-based study
CohnCedermark G; ManssonBrahme E; Rutqvist LE; Larsson O; Singnomklao T; Ringborg U
Review: LAKARTIDNINGEN. 1997;94(28-29):2545-2547
[Melanocytic tumors. Liberal nevus surgery and histopathological scrutiny reduce mortality].
Larsson O; Ringborg U
Review: ACTA OTO-LARYNGOLOGICA. 1996;116(5):641-646
Cutaneous malignant melanoma
Ringborg U
Published conference paper: ACTA ONCOLOGICA. 1996;35(5):76-80
Chemotherapy resistance mechanisms
Ringborg U; Platz A
Published conference paper: DRUGS OF TODAY. 1996;32:51-59
Modulating nitrosourea response in tumors and normal tissue: Application to fotemustine
Margison GP; Rafferty JA; Elder RH; Kelly J; Watson AJ; Willington MA; Lee SM; Hickson I; Fairbairn LJ; Dexter TM; Jelinek J; Stocking C; Baum C; Ostertag W; Eghyazi S; Hansson J; Ringborg U; Donnelly D; McMurry TBH; McCormick J; McElhinney RS
Editorial comment: ACTA ONCOLOGICA. 1995;34(1):1
THE NATURE OF CANCER
RINGBORG U
Other: BRITISH JOURNAL OF CANCER. 1995;71(1):37-39
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITIES IN BIOPSIES OF HUMAN-MELANOMA TUMORS
EGYHAZI S; HANSSON J; RINGBORG U
Visa fler

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI